Randomized trial of topical ascorbic acid in DMSO versus imiquimod for the treatment of basal cell carcinoma
Authors:
Open Access
- 24 February 2022
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 148, 112710
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012JAMA Dermatology, 2015
- Prevalence and Costs of Skin Cancer Treatment in the U.S., 2002−2006 and 2007−2011American Journal of Preventive Medicine, 2015
- Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trialThe Lancet Oncology, 2014
- Comment on “Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer,” i.e., all we are saying is, give C a chanceFree Radical Biology and Medicine, 2011
- Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancerFree Radical Biology and Medicine, 2011
- Long-term follow-up of topical 5-aminolaevulinic acid photodynamic therapy diode laser single session for non-melanoma skin cancerPhotodiagnosis and Photodynamic Therapy, 2009
- Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-upJournal of the European Academy of Dermatology and Venereology, 2009
- Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in miceProceedings of the National Academy of Sciences, 2008
- Fifty-five Basal Cell Carcinomas Treated With Topical Imiquimod: Outcome at 5-Year Follow-upArchives of Dermatology, 2007
- Imiquimod Treatment of Superficial and Nodular Basal Cell CarcinomaDermatologic Surgery, 2005